Sinco Pharmaceutical Holdings (HKSE:06833) Net Income From Continuing Operations : HK$106 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sinco Pharmaceutical Holdings's net income from continuing operations for the six months ended in Dec. 2024 was HK$33 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was HK$106 Mil.

Sinco Pharmaceutical Holdings Net Income From Continuing Operations Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Net Income From Continuing Operations Chart

Sinco Pharmaceutical Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

161.17

204.96

110.88

109.25

105.61

Sinco Pharmaceutical Holdings Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															23.14	46.78	62.47	73.20	33.02

Sinco Pharmaceutical Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$106 Mil.

Sinco Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.

Executives

Huang Zhijian	2305 Beneficiary of a trust
Fullwealth Holdings Limited	2201 Interest of corporation controlled by you
Risun Investments Limited	2101 Beneficial owner
Wickhams Cay Trust Company Limited	2301 Trustee
Huang Xiangbin	2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings Headlines

No Headlines